Chemical and Pharmaceutical Bulletin
Online ISSN : 1347-5223
Print ISSN : 0009-2363
ISSN-L : 0009-2363
Regular Article
Development of Small-Molecule Anti-HIV-1 Agents Targeting HIV-1 Capsid Proteins
Takuya KobayakawaMasaru YokoyamaKohei TsujiSayaka BokuMasaki KurakamiMasayuki FujinoTakahiro IshiiYutaro MiuraSoshi NishimuraKouki ShinoharaKenichi YamamotoPeter BolahOsamu KotaniTsutomu Murakami Hironori SatoHirokazu Tamamura
著者情報
ジャーナル フリー HTML
電子付録

2024 年 72 巻 1 号 p. 41-47

詳細
抄録

The capsid of human immunodeficiency virus type 1 (HIV-1) forms a conical structure by assembling oligomers of capsid (CA) proteins and is a virion shell that encapsulates viral RNA. The inhibition of the CA function could be an appropriate target for suppression of HIV-1 replication because the CA proteins are highly conserved among many strains of HIV-1, and the drug targeting CA, lenacapavir, has been clinically developed by Gilead Sciences, Inc. Interface hydrophobic interactions between two CA molecules via the Trp184 and Met185 residues in the CA sequence are indispensable for conformational stabilization of the CA multimer. Our continuous studies found two types of small molecules with different scaffolds, MKN-1 and MKN-3, designed by in silico screening as a dipeptide mimic of Trp184 and Met185 have significant anti-HIV-1 activity. In the present study, MKN-1 derivatives have been designed and synthesized. Their structure–activity relationship studies found some compounds having potent anti-HIV activity. The present results should be useful in the design of novel CA-targeting molecules with anti-HIV activity.

Fullsize Image
著者関連情報
© 2024 The Pharmaceutical Society of Japan
前の記事 次の記事
feedback
Top